Security
NervGen Pharma Corp Common Stock (Canada) · NRVNF
NRVNFOTCCommon stockHistorical · closed Apr 24, 2019CIK 1751912Updated Oct 19, 2026
Current security for this SEC filerNGEN · NASDAQ
NRVNF price & chart
Historical security
This listing closed Apr 24, 2019. Live provider charts are shown only for current listings.
Current security: NGEN
About the company
NervGen (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic tetraplegia, as demonstrated in the Phase 1b/2a CONNECT SCI study. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need. For more information, visit www.nervgen.com and follow NervGen on X and LinkedIn.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · CADSource
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit or LossCAD | -44,117,305Source | -24,250,049Source |
| Additional Financial Items | ||
| AdjustmentsForSharebasedPaymentsCAD | 5,394,914Source | 6,039,724Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsCAD | -452,134Source | 294,337Source |
| GeneralAndAdministrativeExpenseCAD | 11,172,046Source | 9,365,129Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesCAD | 100,926Source | 100,926Source |
| ProceedsFromIssuingSharesCAD | 16,884,659Source | 23,011,788Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Additional Financial Items | ||
| BasicEarningsLossPerShareCAD/shares | -0.61Source | -0.36Source |
| DepreciationRightofuseAssetsCAD | — | 22,490Source |
| DilutedEarningsLossPerShareCAD/shares | -0.61Source | -0.36Source |
| FinanceIncomeCAD | 333,415Source | 812,617Source |
| GeneralAndAdministrativeExpenseCAD | 11,172,046Source | 9,365,129Source |
| InterestExpenseOnLeaseLiabilitiesCAD | 3,691Source | 9,340Source |
| ResearchAndDevelopmentExpenseCAD | 13,907,206Source | 15,811,020Source |
Filing attachments
tm2627645d1_ex99-1.htm · 6-K/A · 2026-10-16
Exhibit 99.1 Amended and Restated Condensed consolidated interim financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars - Unaudited) For the three months and six months ended June 30, 2026 and 2025 NERVGEN PHARMA CORP. Condensed Consolidated Interim Statements of Financial Position (Expressed in Canadian dollars) (Unaudited) as at June 30, December 31, …
Read attachment ↗tm2627645d1_ex99-2.htm · 6-K/A · 2026-10-16
Exhibit 99.2 Amended and Restated Management’s Discussion and Analysis of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars) For the three and six months ended June 30, 2026 and 2025 Effective Date: October 16, 2026 MANAGEMENT’S DISCUSSION AND ANALYSIS The following discussion is management’s assessment and analysis of the results of operations and financial conditions of NervGen Pharma Corp. (the “Company” or “NervGen”) and should be read in conjunction with the accompanying condensed …
Read attachment ↗ngen-20251231xex99d2.htm · 40-F/A · 2026-10-16
Exhibit 99.2 Amended and Restated Consolidated financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars) For the years ended December 31, 2025 and 2024 Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors NervGen Pharma Corp.: Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated statements of financial position of NervGen Pharma Corp. (the Company) as of December 31, 2025 and 2024,…
Read attachment ↗tm2625558d1_ex99-1.htm · 6-K · 2026-09-24
Exhibit 99.1 NERVGEN PHARMA CORP. NOTICE OF CHANGE OF AUDITOR (National Instrument 51-102 - Continuous Disclosure Obligations ) TO: Ontario Securities Commission British Columbia Securities Commission Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan Manitoba Securities Commission Autorité des marchés financiers Financial and Consumer Services Commission (New Brunswick) Nova Scotia Securities Commission Office of the Superintendent of Sec…
Read attachment ↗tm2625558d1_ex99-2.htm · 6-K · 2026-09-24
Exhibit 99.2 KPMG LLP PO Box 10426 777 Dunsmuir Street Vancouver BC V7Y 1K3 Canada Telephone (604) 691-3000 Fax (604) 691-3031 Ontario Securities Commission British Columbia Securities Commission Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan Manitoba Securities Commission Autorité des marchés financiers Financial and Consumer Services Commission (New Brunswick) Nova Scotia Securities Commission Office of the Superintendent of Securities, Se…
Read attachment ↗tm2623069d1_ex99-1.htm · 6-K · 2026-08-13
Exhibit 99.1 Condensed consolidated interim financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars - Unaudited) For the three months and six months ended June 30, 2026 and 2025 NERVGEN PHARMA CORP. Condensed Consolidated Interim Statements of Financial Position (Expressed in Canadian dollars) (Unaudited) as at June 30, December 31, 2026 …
Read attachment ↗